Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Jeffrey A. Lieberman, T. Scott Stroup, Joseph P. McEvoy et al. · New England Journal of Medicine · 2005 · 5.9K citations · Full text

Medicine, Pharmacotherapy, Psychiatry +14

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans

John H. Krystal · Archives of General Psychiatry · 1994 · 3.3K citations

Medicine, Neuroscience, Pharmacology +13

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

Tiziana Bisogno, Luciano De Petrocellis, Susanna Tchilibon et al. · British Journal of Pharmacology · 2001 · 1.3K citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

F. Markus Leweke, Daniele Piomelli, Franziska Pahlisch et al. · Translational Psychiatry · 2012 · 1.1K citations · Full text

Medicine, Pharmacology, Psychiatry +17

Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States

Jose Ma. J. Alvir, Jeffrey A. Lieberman, Allan Z. Safferman et al. · New England Journal of Medicine · 1993 · 969 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16